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Abstract 
Somnambulism, or sleep walking, is a parasomnia of non-rapid eye movement 
(NREM) sleep where movement behaviours usually confined to wakefulness are 
displayed during sleep. Generally, if sleep walking is causing distress or danger in 
spite of safety measures, medical or psychological treatment is indicated. Clinicians 
will need to assess the evidence for treatment options. Medline, Embase, Psychinfo 
and the Ovid EBM multifile databases were searched. No properly powered rigorous 
controlled trials were found for treatment of sleepwalking in adults. Seven reports 
described small trials with some kind of control arm, or retrospective case series 
which included 30 or more somnambulism patients. With no high quality evidence to 
underpin recommendations for treatments of somnambulism, full discussion with 
patients is advised. Adequately powered, well designed clinical trials are now needed, 
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Background and aim for review 
There are several recent reviews of somnambulism (sleepwalking)1, 2 and the larger 
field of parasomnias.3-7 These give clinical features, epidemiological information, 
genetics and the relationship of somnambulism to other sleep abnormalities. They also 
suggest medical treatments for the condition but usually without showing the 
evidence base for each treatment option. This review therefore provides brief 
background information, but focuses primarily on an examination of evidence to 
support treatments commonly suggested for somnambulism. 
Somnambulism 
Somnambulism (also known as sleep walking) is a type of parasomnia, disorders 
where usual distinctions between wakefulness, REM and NREM sleep are blurred.4 
Somnambulism is a disorder of arousal occurring during NREM sleep (stages 3 and 
4).7 NREM parasomnias are classified largely by behaviours displayed and 
somnambulism is closely related to other NREM parasomnias (confusional arousals, 
sleep terrors, sleep related sexual behaviour, and sleep-related violence). Sleep-related 
eating disorder is a further, recently described NREM parasomnia variant8 
Parasomnias of REM sleep, such as REM-sleep behaviour disorder, are a separate 
classification and not included in this review.  
While this review deals with somnambulism in adults, the condition is more common 
in children. The prevalence in adults is 2-3% with nightly sleepwalking in only 0.4%.1 
Some 80% of adult sufferers also had childhood somnambulism.9 Prevalence appears 
unaffected by gender or socio-economic status, but has a genetic basis.10, 11 
Various drugs, most recently Zolpidem,12 have been reported to be associated with 
sleepwalking but this is controversial, being based on small numbers of cases and 
often without thorough investigation of alternative causation.13 Among those who 
exhibit sleep walking, an episode can follow sleep deprivation.1 Early research looked 
for relationships between various psychopathologies and somnambulism 2, 7 but 
consistent relationships have not been found and purely physiological causes are now 
proposed.14-16  
Sleepwalking episodes usually occur in the first third of the night, during non-
dreaming, slow wave, sleep. Movements may be fairly minor but may extend to 
leaving the bed and walking. Eyes are often open and the sleepwalker may mumble. 
Movement is clumsy but if uninterrupted the person can usually safely return unaided 
or gently aided to a lying position and continue their sleep. At the extreme, complex 
behaviours such as driving a car have been documented. If interrupted and aroused, 
for example to prevent accidents, the sleep walker may or may not be agitated or 
violent. There is usually no memory on waking of the sleepwalking event.7  
Measures such as avoiding sleep deprivation or other apparent priming factors, 
removing hazards and giving the sleepwalker quiet guidance back to bed if necessary, 
are advocated as first line treatment, along with reassurance that sleepwalking is not 
linked with underlying psychiatric illness.3  Medical treatment is needed for adult 
sleepwalking only if these measures have been taken and the condition is still causing 
distress or danger. In this situation, clinicians will wish to assess the evidence for 
treatment options. 
Suggested treatments for trial with individual patients include the benzodiazepines 
diazepam, triazolam, temazepam, estazolam and clonazepam, zolpidem, tricyclic 
antidepressants including imipramine, the selective serotonin reuptake inhibitor 
antidepressant paroxetine and the related drug trazodone, and hypnosis, guided 
imagery and relaxation training.2, 3, 7, 17, 18 However treatments are frequently 
suggested without reference to supporting studies, or with reference to case reports 
only. Reports of systematic searches and appraisals of somnambulism treatments are 
not available. This review therefore presents a comprehensive search for evidence of 
effectiveness of treatments which have been advocated for somnambulism, an 
assessment of that evidence and implications for clinical practice and further research. 
Search 
Searches were carried out 17 July 2008 in Medline, Embase, Psychinfo and the Ovid 
EBM multifile database as follows.  
Medline [1950 forward] somnambulism/th,dt OR parasomnias/th,dt 
Embase [1980 forward] sleep walking/th,dt OR paasomnia/th,dt 
Psychinfo [1806 forward] *sleepwalking/ 
Ovid All EBM Reviews - 
Cochrane DSR, ACP Journal Club, 
DARE, CCTR, CMR, HTA, and 
NHSEED 
somnambulis$ OR sleep?walk$ OR parasomnia$ 
In each case the relevant McMaster University HIRU high sensitivity filter for 
retrieval of scientifically sound studies of therapy evaluations was included.19 
Abstracts were scanned, and full text obtained for reports likely to describe formal 
evaluations of therapy for sleepwalking as a primary complaint and in adults. 
Reference lists of studies obtained were also assessed. Descriptions of management of 
single or small numbers (6 or less) of cases were rejected. 
Results 
No properly powered controlled trials were found for sleepwalking in adults. Seven 
reports described small trials with some kind of control arm, or case series which 
included 30 or more somnambulism patients.  
• In a single blind prospective comparison of “active “hypnotherapy (n=7) 
compared to “suggestion” hypnotherapy (n=4) with some subsequent 
crossover, no benefit could be ascribed to active therapy.20 
• In a double-blind crossover trial of diazepam for sleepwalking in 5 adults, 
though authors stated that some or all self-reported symptoms were alleviated 
for some participants, results failed to show significant difference between 
placebo and diazepam.21 
• Another report followed up 60 sleep walking young adults 1 year after they 
had been treated according to a defined protocol. Patients were assessed for 
sleep disordered breathing and offered CPAP or surgery if there was even mild 
SDB (all but 6 cases) or benzodiazepines if there was not. Patients with SDB 
and either compliant with CPAP or having had surgery reported resolution of 
sleep walking. Authors concluded that treating any comorbid SDB also 
resolved sleepwalking in young adults.22 
• Four reports of large mixed case series included patients with sleepwalking 
but did not report all outcomes separately for the sleep walking patients. One 
series included 61 patients treated with clonazepam, 28 of them having night 
terrors/sleep walking, and 83.6% of the 61 were reported as achieving “rapid 
and sustained control”. A further 22 patients with night terrors/sleep walking 
both learned and used self-hypnosis and 14 “achieved substantial benefit”.23 In 
another mixed series 86% of 170 patients self-reported “complete/nearly 
complete” control after 4 months to 12 years of benzodiazepine treatment. 
Sixty nine of the group had “sleep terrors/sleepwalking”. 24 In a further case 
series 23 patients with sleepwalking were among a group of 27 available for 
follow-up after undergoing self hypnosis training. Twenty of the whole group 
self- reported “very much or much improvement” and a lower retrospectively 
estimated frequency of spells when contacted 6 months to 5 years after 
treatment.25 Another series of 32 adults and 4 children referred by a sleep 
physician for hypnosis included 11 diagnosed with sleepwalking. Six of the 11 
responded to 18month follow-up and 3 of the 6 said they were “spell-free or 
much improved” while the other 3 reported “little or no improvement”. 26   
Discussion  
Benzodiazepines are frequently recommended as an effective treatment for 
somnambulism. However, adequately powered randomised controlled trials are 
lacking for this and other medical and psychological treatments for somnambulism. 
Observational evaluations have generally been retrospective, have included no 
untreated comparison group, and have relied solely on self-report of improvement by 
patients available for follow-up as outcome measures. Clinicians may be surprised to 
learn that very low level evidence supports recommendations for treatments of 
somnambulism. Full discussion with patients is advised where this kind of “off-label” 
prescription is being considered and, if the decision is to prescribe, written patient 
consent is recommended.27 As evidence is lacking for pharmacological treatments, 
clinicians may wish to ensure that patients are fully informed about all options 
including environmental safety measures. 
Somnambulism is an infrequent but often distressing condition28 and better evidence 
is needed to support treatment decisions by clinicians and patients. The low 
prevalence of somnambulism needing treatment, the low frequency of episodes in 
many subjects, and difficulties in designing rigorous outcome measures may in the 
past have been barriers to well powered randomised controlled trials.29 However there 
are now strategies to overcome these problems. Research designs and biostatistical 
approaches are available for trials in rarer diseases30, 31 and research collaborations 
can be formed for multicentre clinical trials which can recruit enough patients by 
including many centres nationally and internationally. New laboratory-based 
somnambulism episode-precipitating techniques32 and longer-term electronic self-
reporting from home33 are now available to provide for more rigorous outcome 
measurement in these trials. 
The lack of good evidence for the usual pharmacological treatment of somnambulism 
is important, especially in view of the use of sleepwalking as a defence in medico-
legal settings, and a well-designed multi-centre trial is now needed. 
Practice points 
• Benzodiazepines are often recommended but adequately powered randomised 
controlled trials are lacking for medical and psychological treatments for 
somnambulism.  
• Both clinicians and patients should be aware of the lack of good evidence of 
effectiveness if medical treatment is being considered. 
Research agenda 
• Better evidence is needed to support treatment decisions in somnambulism.  
• Adequately powered randomised controlled trials are now needed and can be 
conducted through multi-centre collaborations.  
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